BostonGene touts prostate cancer research results

By The Science Advisory Board staff writers

July 29, 2021 -- Biomedical software firm BostonGene is highlighting research published in Clinical Cancer Research that identified particular molecular, cellular, and structural characteristics associated with magnetic resonance imaging (MRI)-visible, clinically significant prostate cancer.

The research was conducted by a team of oncologists at Washington University School of Medicine in St. Louis in partnership with the company. The investigators conducted a multiomics analysis of multiparametric MRI (mpMRI)-invisible and visible prostate cancer using BostonGene's artificial intelligence (AI)-based immunofluorescence single-cell spatial imaging and gene expression profiling.

In addition to identifying characteristics of MRI-visible, clinically significant prostate cancer, the researchers also found that tumors invisible on mpMRI were similar to normal prostate tissue. What's more, the expression profiling identified a stromal enrichment signature in mpMRI-invisible prostate cancers that correlated with better clinical outcomes, according to the researchers.

"This AI-based analytical approach could distinctly identify the molecular and cellular composition of tumor tissue," said study lead author Dr. Russell Pachynski in a statement released by BostonGene. "Integrated multiomics analysis in conjunction with mpMRI shows promise for the diagnosis and personalization of treatment options for patients with clinically significant prostate cancer."


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here